Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: A new mode of catalytic inhibition

Molecular Pharmacology

Volumn 61, Issue 5, 2002, Pages 1235-1243

  Jensen, Lars H ^a,b,c   Renodon Corniere, Axelle ^a,b,c   Wessel, Irene ^a,b,c   Langer, Seppo W ^a,b,c   Søkilde, Birgitte ^a,b,c   Carstensen, Elisabeth V ^a,b,c   Sehested, Maxwell ^a,b,c   Jensen, Peter B ^a,b,c  

^a FINSEN LABORATORY   (Denmark)

^b Laboratory Center   (Denmark)

^c BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DAUNORUBICIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; MALEIMIDE; MALEIMIDE DERIVATIVE; N ETHYLMALEIMIDE; PIPERAZINE DERIVATIVE; SUCCINIMIDE DERIVATIVE;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL LINE; CLONOGENIC ASSAY; CONTROLLED STUDY; COVALENT BOND; DNA CLEAVAGE; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; ELUTION; ENZYME MODIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATALYSIS; CELL SURVIVAL; CELLS, CULTURED; DAUNORUBICIN; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DRUG INTERACTIONS; ETHYLMALEIMIDE; ETOPOSIDE; HUMANS; MALEIMIDES;

EID: 0036239375     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.5.1235     Document Type: Article

References (36)

1. Catalytic inhibitors of DNA topoisomerase II
2. Topoisomerase II-mediated cleavage of plasmid DNA
3. Establishment and identification of small cell lung cancer cell lines having classic and variant features
4. DNA Topoisomerases: Essential enzymes and lethal targets
5. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung
6. Merbarone inhibits the catalytic activity of human topoisomerase II α by blocking DNA cleavage
7. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells
8. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide
9. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors
10. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines
11. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to Taxotere, Taxol, topotecan and gemcitabin
12. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: Relationship to DNA integrity and topoisomerase II
13. A novel mechanism of cell killing by antitopoisomerase II bisdioxopiperazines
14. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
15. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming tepoisomerase II-related drug resistance
16. N-Terminal and core-domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistance
17. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL)
18. Decreased topoisomerase II α expression confers increased resistance to ICRF-193 as well as vp-16 in mouse embryonic stem cells
19. Fractionation of DNA from mammalian cells by alkaline elution
20. Inhibitors of topoisomerase II as pH-dependent modulators of etoposide-mediated cytotoxicity
21. Treatment of anthracycline extravasation with dexrazoxane
22. DNA Topoisomerase poisons as antitumor drugs
23. Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193
24. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase ii by trapping the enzyme in the form of a closed protein clamp
25. The capture of a DNA double helix by an ATP-dependent protein clamp: A key step in DNA transport by type II DNA topoisomerases
26. DNA transport by a type II DNA topoisomerase: Evidence in favor of a two-gate mechanism
27. A quantitative decatenation assay for type II topoisomerases
28. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: A Tyr49Phe mutation confers highlevel resistance to bisdioxopiperazines
29. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation of cleavable-complex formation by etoposide but not by amsacrine
30. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives
31. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: A potent tool for identification and characterization of topoisomerase ii-targeting antitumour agents
32. DNA topoisomerases
33. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation
34. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional r162q mutation in the walker a consensus ATP binding domain of the a isoform
35. Loss of amino acids 1490Lys-Ser-Lys 1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization
36. Four out of six human small cell lung cancer cell lines resistant to ICRF-187 have either R162Q or Y165S functional mutations in the Walker A ATP binding site